Handouts as of 9/17/18 Respiratory Allergic Rhinitis: I Can't Breathe! (CME300‐301) Asthma Updates (CME302‐303) Bronchiolitis and Respiratory Syncytial Virus (RSV) (CME304‐305) Chronic Obstructive Pulmonary Disorder (COPD): A Breath of Fresh Air (CME306‐307) Pneumonia: The Forgotten Killer (CME308‐309)
202
Embed
Respiratory Allergic Rhinitis: I Can't Breathe! (CME300 ...€¦ · using this material and for all claims that might arise out of the use of the techniques ... Determine when patients
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Handouts as of 9/17/18
Respiratory
Allergic Rhinitis: I Can't Breathe! (CME300‐301)
Asthma Updates (CME302‐303)
Bronchiolitis and Respiratory Syncytial Virus (RSV) (CME304‐305)
Chronic Obstructive Pulmonary Disorder (COPD): A Breath of Fresh Air (CME306‐307)
Pneumonia: The Forgotten Killer (CME308‐309)
1
Allergic Rhinitis: I Can’t Breathe!
Sheryl M. Beard, MD, FAAFP
ACTIVITY DISCLAIMERThe material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note that medical information is constantly changing; the information contained in this activity was accurate at the time of publication. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.
The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.
2
DISCLOSUREIt is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity.
All individuals in a position to control content for this session have indicated they have no relevant financial relationships to disclose.
The content of my material/presentation in this CME activity will not include discussion of unapproved or investigational uses of products or devices.
Sheryl M. Beard, MD, FAAFPSenior Associate Program Director, Via Christi Family Medicine Residency, Wichita, Kansas; Clinical Assistant Professor, Department of Family and Community Medicine, University of Kansas (KU) School of Medicine–Wichita
Dr. Beard earned her medical degree from the KU School of Medicine–Wichita and completed her family medicine residency at the Via Christi Family Medicine Residency in Wichita. Following residency, she joined the U.S. Air Force and was stationed at McConnell Air Force Base in Wichita, Kansas. Prior to beginning her academic career, she served a brief tour in Iraq at Kirkuk Air Base in 2006 and spent a short time in private practice. Dr. Beard became a faculty member at Via Christi in 2008 and has been the Senior Associate Program Director since 2009.
3
Learning Objectives1. Identify the signs and symptoms of rhinitis and use appropriate tools
to diagnose and differentiate between allergic and non-allergic rhinitis.
2. Determine when patients require referral to sub-specialists for enhanced evaluation and/or treatment of rhinitis.
3. Prepare treatment plans for rhinitis based on each patient’s specific sensitivities and symptoms and the possibility of persistent inflammation and comorbidities, and make adjustments if the patients experiences epistaxis.
4. Educate patients regarding appropriate treatment protocol for rhinitis and the responsible use of antibiotics when prescribed as necessary.
Audience Engagement SystemStep 1 Step 2 Step 3
4
Practice Recommendations• Identify and treat patients for allergic rhinitis to
improve control of asthma (SOR B)
• Effectively implement correct use of intranasal steroids in patients with allergic and non-allergic rhinitis (SOR A)
• Make appropriate referrals to an allergist/immunologist for allergic rhinitis patients refractory to other treatments (SOR C)
Classification
• Temporal– Seasonal
– Perennial
– Episodic
• Frequency
• Severity-mild vs severehttps://www.freeimages.com/photo/poppies-1369329
5
Definitions
• Allergic rhinitis (AR)
• Seasonal AR
• Perennial AR
• Intermittent AR
• Persistent AR
• Episodic AR
Epidemiology
• 30-60M annually
–10-30% adults
–40% children
• 2005- $11B
6
Barriers to Care
• Trivial disease
• Considered educated about disease
• Untreated/undertreated3
– Asthma and allergic conjunctivitis less so
• Side effects, poor technique, cost
Chronic Comorbid Conditions• Asthma
• Atopic dermatitis
• Sleep disordered breathing
• Conjunctivitis
• Rhinosinusitis
• Otitis media
7
Case #1
• 9 yo female presents with one month hxcongestion, runny nose, sneezing, and nighttime cough
• She has peanut allergy diagnosed at the age 9 months and severe eczema as a child, but is now very well controlled and intermittent
AES Question #1What percentage of patients with asthma also have allergic rhinitis?
A. 5%
B. 10%
C. 20%
D. 50%
E. 80%
8
Asthma
• 80% with asthma have AR
• 40% with AR have asthma
• Children severity and duration
• “Allergic march”
Impact• 1 in 5 mod/sev impact
• > 50% impact sleep, fatigue
• 74% neg impact sleep daily activities
• Assess severity with tools
– WPAI-AS3
– Visual analog scale
9
Pathogenesis
• Allergen exposure
• Presenting cells
• Invite inflammatory cells
• Release inflammatory mediatorsRhinorrhea
• Sneezing • Rhinorrhea• Congestion• Nasal obstruction• Post nasas drip • Pruritis• Asthma or sxs• Children: malaise or fatigue
History• Frequency• Duration• Environmental triggers• Seasonality• Medications• FH of atopic disease• Sxs with irritant exposure• URI sxs
10
Physical Exam• Clear rhinorrhea
• Pale or bluish nasal mucosa
• Nasal congestion
• Red watery eyes
• Throat clearing
• Allergic shiners
• Nasal crease
• Absence of FB, purulence Photo used with permission
References1. Seidman MD, Gurgel RK, Lin SY, et al. Clinical Practice Guideline-Allergic
Rhinitis. Otolaryngology-Head and Neck Surgery. 2015 Feb;152(1_suppl):S1-S-43
2. Wallace DV, Dykewicz mS, Berstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. The Journal of allergy and clinical immunology. 2008;122(2suppl):S1-S84
3. Carr WW, Yawn BP. Management of allergic rhinitis in the era of effective over-the-counter treatments. Postgraduate medicine. 2017
4. Sur DK, Plesa ML. Treatment of Allergic Rhinitis. American Family Physician. 2015;92(11):985-992.
5. Carr, WW, New therapeutic options for allergic rhinitis: back to the future with intranasal corticosteroid aerosols. American journal of rhinology & allergy. 2013;27(4):309-313.
1
Asthma Updates
Mark Shaffer, MD, FAAFP
ACTIVITY DISCLAIMERThe material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note that medical information is constantly changing; the information contained in this activity was accurate at the time of publication. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.
The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.
This CME session is supported by an educational grant from GlaxoSmithKline.
2
DISCLOSUREIt is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity.
All individuals in a position to control content for this session have indicated they have no relevant financial relationships to disclose.
The content of my material/presentation in this CME activity will not include discussion of unapproved or investigational uses of products or devices.
Mark Shaffer, MD, FAAFPAssistant Professor, Department of Family and Preventive Medicine, University of South Carolina School of Medicine, Columbia, South Carolina; Medical Director, John A. Martin Primary Health Care Center, Winnsboro, South Carolina
Dr. Mark Shaffer has been a member of the faculty with the University of South Carolina School of Medicine’s Department of Family and Preventive Medicine since 2015. He practices and teaches full spectrum family medicine with obstetrics and is the medical director for a rural health center, which is his primary practice location. He serves as the Tanzania site director for the department’s global health fellowship. His areas of interest are childhood obesity, point-of-care ultrasound and global health. Dr. Shaffer earned his medical degree from Harvard Medical School in Boston, MA, and then completed family medicine residency at Palmetto Health Richland Hospital in Columbia, SC. After residency, he felt called to international service and became the inaugural fellow in a one year Global Health Fellows program in Mbeya, Tanzania. He remained in Tanzania as the clinical director for a large HIV/AIDS prevention and treatment program until his return to academia stateside.
3
Learning Objectives1. Use evidence-based criteria to order and interpret appropriate
tests for asthma.
2. Analyze environmental triggers for asthma with patients and select factors to reasonably avoid or control them.
3. Develop system-wide interventions that promote patient adherence to long-term management of chronic asthma.
4. Collaborate with asthma patients to develop an asthma action plan that encourages adherence.
Audience Engagement SystemStep 1 Step 2 Step 3
4
Key Points
• PFTs should be used as part of the diagnosis of asthma for patients over 5.
• Use of simple in-office tools can make a huge impact on patient outcomes.
• Consider vitamin D, LAMAs, SMART therapy and Biologics as effective treatment options.
Outline
• Review of Asthma Diagnosis and Evaluation
• Review of Traditional Asthma Management
• Novel Therapies
5
Diagnosis and Evaluation
• Differential Diagnosis
• Role of Spirometry
• Environmental Evaluation
Diagnosing Pediatric Asthma
• 30% of Children Wheeze by Age 6
• PFTs not recommended until over age 5
• What can you do!Weiss LN. The diagnosis of wheezing in children. American family physician.2008;77(8):1109-1114.
6
How do I Diagnose Asthma?To establish a diagnosis of asthma, the clinician should determine that (EPR 2 1997):• — Episodic symptoms of airflow obstruction
or airway hyper-responsiveness are present.• — Airflow obstruction is at least partially
reversible.• — Alternative diagnoses are excluded.
Guidelines for the Diagnosis and management of Asthma. Full Report 2007. National Asthma Education and Prevention Program. 2007.
Krafczyk, M and Asplund, C. Exercise-Induced Bronchoconstriction: Diagnosis and Management. Am Fam Physician. 2011 Aug 15;84(4):427-434.
13
Exercise Induced Bronchospasm
• Trigger avoidance/Awareness
• Short acting Beta Agonist pre-exercise– If asthmatic need controller agent as well
– Avoid daily use
• Leukotriene Receptor Antagonist– Up to 24 hours preventive effect
AES Question
Using a standardized office tool to assess asthma may decrease exacerbations by:A. 10-20%B. 20-30%C. 30-40%D. >40%
14
• Organized approach to asthma assessment for Primary Care
• Validated with the ACT
• Studied with large multicenter randomized controlled trial
Asthma Apgar
Rank MA, Bertram S, Wollan P, Yawn RA, Yawn BP. Comparing the Asthma APGARsystem and the Asthma Control Test in a multicenter primary care sample. Mayo Clinic proceedings Mayo Clinic. 2014;89(7):917-925.
APGAR
• Activities
• Persistence
• TriGgers
• Asthma Medications
• Response to MedicationsYawn BP, Bertram S, Kurland M, et al. Protocol for the asthma tools study: a pragmatic practice-based research network trial. Pragmat Observ Res. 2013;4:1-12.
15
Asthma Apgar
• More than doubled documentation of Triggers,
Med Adherence and Nighttime Symptoms
• 70% of questionnaires revealed an actionable item
• Use of APGAR reduced acute care exacerbation rate
by 50% Yawn, Bertram and Wollan. Introduction of Asthma APGAR tools improve asthma management in primary care practices. Journal of Asthma and Allergy 2008: I 1-10
Practice Recommendations
• Obtain PFTs for any patient over age 5 prior to making an asthma diagnosis.
• Use an standardized approach to asthma assessment such as the APGAR
• Consider monteleukast for frequent exercise induced bronchospasm
16
Traditional Asthma Management
• Stepwise Approach
• Asthma Action Plan
• Inhaler Teaching and Use
Assessment
• Severity: How severe are symptoms when NOT on medications?
• Control: How severe are symptoms when on medications?
• Adjust medications based on assessment.
17
Example Patient
Tyrone, 36 year old man with untreated asthma. • Gets winded at work 3-4 x per week• Wakes up about 1 week short of breath• Otherwise living and working well.• His PFTs showed FEV1 85% predicted,
reversible with SABA
AES QuestionIn addition to trigger control, which of the following is a recommended initial treatment for Tyrone?A. SABA PRNB. SABA+ fluticasone 110mcg BID C. SABA+ fluticasone 220mcg BIDD. SABA+
National Asthma Education and Prevention Program Asthma Care Quick Reference. September 2011. https://www.nhlbi.nih.gov/files/docs/guidelines/asthma_qrg.pdf accessed 7.2.18
Gibson PG et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003;(1):CD001117.
Asthma Update!• Vitamin D
• LAMAs for Asthma
• SMART Asthma Management
• Biologics
21
Vitamin D and Asthma
• Antimicrobrial and Antiflammatory
• Increases response to Steroids
• Common Deficiency in Asthmatic
Qiu J. Vitamin D for the Management of Asthma. American family physician.2017;96(5):290-291.
Vitamin D and Asthma
• Decreased exacerbations by 37% (absolute RR of 3.8% of hospital visit)
• No clear dosage guideline, median dose 900 IU per day range 400-4000
• No change in Asthma Quality of LifeQiu J. Vitamin D for the Management of Asthma. American family physician.2017;96(5):290-291.
22
LAMAslong-acting muscarinic antagonists
• ICS+ LABA ~ ICS + LAMA
• ICS+ LABA+LAMA– No significant reduction in exacerbations or
quality of life
– Small reduction in risk of progressionSobieraj DM, Baker WL, Nguyen E, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma. A systematic review and meta-analysis. JAMA 2018;319(14):1473-1484.
Why Chose LAMA?
• Side effects from LABA therapy– Anxiety/Palpitations/Hypokalemia
• No concerns for anticholinergic effects– BPH, CrCl< 60, polypharmacy
• Not sure what they have…
23
AES Question
Combination steroid/LABA medications may be effectively used in a PRN fashion.
A. TRUE
B. FALSE
How are you doing with those inhalers?
• “They work great doc!”
• “I take the albuterol twice a day every day”
• “…And that Advair whenever I need it.”
24
SMART Asthma Therapy
• Single Maintenance and Reliever Therapy
• Reduced Exacerbations (3% absolute risk)
• Similar Quality of Life and FEV1Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting B-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma. A systematic review and meta-analysis. JAMA 2018;319(14):1485-1496.
Writing SMART
• Budesonide/formoterol 80mcg/4.5mg
• 1 puff twice daily and
• As needed up to 6x more per day (8 doses total)
25
SMART Prescribing
• Most studied form not available in US(Budesonide 100/Formoterol 6 dry powder)
• Part of international guidelines/off label in USA
• Salmeterol much longer onset of action-not appropriate for SMART
Global Initiative for Asthma. Global strategy for asthma management and prevention, 2017. http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/. Accessed June 18, 2018.
Practice Recommendations
• Vitamin D will reduce exacerbation risk for most patients with asthma
• LAMA medications are an effective alternative to LABAs
• SMART therapy with budesonide/ formoterol may superior to traditional therapy
26
Biologics
• Immunoglobin therapy to reduce inflammation underlying asthma.
• Expensive but effective
• No specific “asthma Antigen”
Who Gets Them?
Uncontrolled patients with asthma with:
• Proven specific allergen sensitivity or– Anti IgE
Benralizumab IL-5 R alpha SC q 4 weeks Helminths $5,702
Prescribing Information Benralizumab. AstraZeneca. https://www.azpicentral.com/fasenra/fasenra_pi.pdf#page=1. Accessed 7.7.18Prescribing Information Reslizumab. Teva Pharmaceautical Industries. http://cinqair.com/pdf/PrescribingInformation.pdf. Accessed 7.7.18Prescribing Information mepolizumab. GlaxoSmithKline. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL.PDF. Accessed 7.7.18Lexicomp Omalizumab Drug information. Accessed 7.7.18
Practice Recommendations
• Consider IgE and Eosinophilia testing in uncontrolled patients with asthma to evaluate for immunotherapy
• Be prepared to manage anaphylaxis if overseeing immunotherapy
30
Older Biologics (Herbs)
• ASHMI- Antiasthma herbal medicine intervention formulation
• Ling-Zhi, Ku-Shen and Gan-Gao• Similar efficacy to oral prednisone, less
side effects, no large trialsWen et al. Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma. J Allergy Clin Immunol. 2005 Sep;116(3):517-24.
Key Points
• PFTs should be used as part of the diagnosis of asthma for patients over 5.
• Use of simple in-office tools can make a huge impact on patient outcomes.
• Consider vitamin D, LAMAs, SMART therapy and Biologics as effective treatment options.
Bronchiolitis and Respiratory Syncytial Virus (RSV)
William R. Sonnenberg, MD, FAAFP
ACTIVITY DISCLAIMERThe material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note that medical information is constantly changing; the information contained in this activity was accurate at the time of publication. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.
The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.
2
DISCLOSUREIt is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity.
All individuals in a position to control content for this session have indicated they have no relevant financial relationships to disclose.
The content of my material/presentation in this CME activity will not include discussion of unapproved or investigational uses of products or devices
William R. Sonnenberg, MD, FAAFPFamily physician, Titusville, Pennsylvania; Clinical Assistant Professor of Family and Community Medicine, Penn State College of Medicine, Hershey, Pennsylvania
Dr. Sonnenberg earned his medical degree from the University of Pittsburgh and completed his family medicine residency at McKeesport Hospital in Pennsylvania. A former president of the Pennsylvania Academy of Family Physicians, he has been in private practice in the Titusville, Pennsylvania, area since 1983. In 2017, he was a featured speaker about pneumonia and inflammatory bowel disease in three issues of the AAFP’s FP Audio™. His lectures at national meetings have been selected for publication by Audio-Digest seven times. 2018 marks his 11th time presenting at the AAFP’s annual meeting.
3
Learning Objectives1. Identify the risk factors for bronchiolitis and the indications for
aggressive treatment including hospitalization.
2. Utilize comprehensive, evidence-based, and cost effective strategies for the evaluation of bronchiolitis.
3. Prescribe appropriate prevention strategies for children who are at increased risk for bronchiolitis.
4. Council patients regarding appropriate supportive care for patients who have bronchiolitis.
Audience Engagement SystemStep 1 Step 2 Step 3
4
Key Guidelines from AAP and AAFP
• The diagnosis of bronchiolitis and assessment of disease severity should be based on history and physical examination. Laboratory and radiologic studies should not be routinely ordered for diagnosis.
• Risk factors for severe disease such as age < 12 weeks, premature birth, underlying cardiopulmonary disease, or immunodeficiency should be assessed when making decisions about evaluation and management of children with bronchiolitis.
• Bronchodilators (albuterol, salbutamol), epinephrine, and corticosteroids should not be administered to infants and children with the diagnosis of bronchiolitis.
• Nebulized hypertonic saline should not be administered to infants with the diagnosis of bronchiolitis in the emergency department. Nebulized hypertonic saline may be administered to infants and children hospitalized for bronchiolitis.
• Antibiotics should not be used in children with bronchiolitis unless there is a concomitant bacterial infections
• Supplemental oxygen is not necessary in children and infants with a diagnosis of bronchiolitis if SpO2 exceeds 90%.
• Continuous pulse oximetry is optional for infants and children with bronchiolitis.
• Chest physiotherapy should not be used in the management of bronchiolitis.
• Palivizumab prophylaxis should be administered during the first year of life to infants with hemodynamically significant heart disease or chronic lung disease of prematurity (<32 weeks gestation who require >21% O2 for the first 28 days of life).
• To prevent spread of respiratory syncytial virus (RSV), hands should be decontaminated before and after direct contact with patients, after contact with inanimate objects in vicinity of patient, and after removing gloves. Alcohol rubs are the preferred method for hand decontamination. Clinicians should educate personnel and family on hand sanitation.
• Infants should not be exposed to tobacco smoke.
• Exclusive breastfeeding for at least 6 months is recommended to decrease the morbidity of respiratory infections.
5
Bronchiolitis
Viral URI followed by increased respiratory effort and wheezing
Less than age 2
American Academy of Pediatrics, Subcommittee on Diagnosis and Management of Bronchiolitis. Pediatrics. 2006;118(4):1774–1793
Scope of Problem
• Most common lower respiratory tract infection in infants younger than age 2
• 60% of LRTI’s in first year of life
• Leading cause of hospitalization in younger than age one
• Hospitalizations have declined from 2000 to 2010
• 4500 deaths/yr 1985 to ≈ 12 deaths/yr nowShay DK et al. Infect Dis. 2001;183 :16 –22
Leader S, et al. J Pediatr. 2003;143(5 suppl) :S127 –S132The Lancet, Aug 20,2016
6
Leading Cause of Infant Hospitalization
73,250
87,826
181,662
220,379
0 50,000 100,000 150,000 200,000 250,000
Dehydration
Jaundice
Bronchiolitis
RSV Bronchiolitis
Leader S, Kohlhase K. Pediatr Infect Dis J. 2002;21:629-632
Epidemiology of Bronchiolitis
Bronchiolitis Statistics
• 90% children 0-2 yrs infected with RSV
• 20% have lower respiratory infection
• 3% hospitalized
• 0.002% mortality
Age at Presentation
• Peak age 2-5 months
• Mean age 3 months
• Rare in 1st month of life
7
Sex Epidemiology
• Male : Female
– Hospitalized infants 2:1
– Milder RSV disease 1:1
• Sex influences expression of illness rather than attack rate
• Preschool and daycare increases riskHall CB. RSV. Textbook of Pediatric Infectious Disease
Wikicommons
Socioeconomic Factors• Lower socioeconomic infants have
increased risk of infection
• Higher socioeconomic infants tend to be older, thus have milder disease
• More hospitalized infants are lower socioeconomic
– Daycare, crowded living quarters
Hall CB. RSV. Textbook of Pediatric Infectious Disease Wikicommons
8
Risk Factors
Cigarette smoke exposureCigarette smoke exposureYounger than 6 months
Crowded conditionsLack of breast feeding
Premature before 37 weeksBirth order ≥ 2nd
Risk and Prematurity
17.3
4.7
1
0
2
4
6
8
10
12
14
16
18
20
<32 wk GA 32-35 wk GA ≥36 wk GA
Odd
s Ra
tio o
f Bro
nchi
oliti
s D
eath
Holman RC et al. Pediatric Infect Dis.
2000;22:433-439
9
Premature at High Risk
• Immature lung development
– Altered airway anatomy
– Reduced lung function through early childhood
• Immature immune system
– Impaired humoral and cellular immunity
Creative Commons Attribution 2.0 Generic
Interrupted Lung Development
Medimmune
10
Antibody Levels in Premature
200
320
520
1100
0
200
400
600
800
1000
1200
<28 wks GA 28-31 wks GA 32-35 wks GA Term
Seru
m Ig
G(m
g/10
0ml)
Yeung CY, Hobbs JR. Lancet. 1968;7553:1167-70
Prematurity and RSV
(Stevens TP et al. Arch Ped Adoles Med 2000)
RSV Hospitalization Rate by Gestational Age at Birth
20.6%
14.6%11.3%
6.4%
0%
5%
10%
15%
20%
25%
<= 26 wks 27-28 wks 29-30 wks 31-32 wks
11
80% RSV admissions occur within 4 months discharge from
NICU
Wikicommons
NICU Discharge and RSV Admissions
42.0%
27.0%
16.0%
41.0%
0%
10%
20%
30%
40%
50%
Jan Feb-Apr May-Aug Sept-Dec
Respiratory Illness Hospitalization Rate by Month of Discharge from NICU in Infants <= 32 Weeks
• Keep sick school-age children away from younger siblings (under 2 years of age)
• Minimize visitors with an infant
• Avoid crowded places
– Malls, grocery stores
• If possible, avoid daycare during RSV season
wikicommons
32
RSV Viability
• Hard surfaces 6 hours
• Rubber gloves 90 minutes
• Skin 20 minutes
Breast Feeding – Always the Right Answer
• Hazard ratio for no breast feeding 1.57 at 12 months
• Risk for exclusive breast feeding similar to breastfed with formula
Lanari M et al. Early Hum Dev. 2013 Jun;89 Suppl 1:S51-7
33
Palivizumab
• Administer in first year of life
– Hemodynamically heart disease
– Chronic lung disease of prematurity
• <32 weeks gestation who require >21% O2 for the first 28 days of life
Pediatrics November 2014, VOLUME 134 / ISSUE 5From the American Academy of Pediatrics Clinical Practice Guideline
Palivizumab
• Monoclonal antibody to F protein of RSV
– 55% ↓ hospitalizations for preterm/chronic lung disease
– 45% ↓ hospitalizations for congenital heart disease
34
Cost-Effectiveness
• Kansas Medicaid Study
– Reduced hospitalization – 0.47 odds
– Shorter length of stay - 74%
– Less inpatient costs - $703
– No deaths in either group
• Costs 6.67 times as much as no treatment
• About $6,000 per seasonArch Pediatr Adolesc Med. 2002 Dec;156(12):1251-5
Palivizumab and Wheezing in Healthy Preterm Infants
• Preterm 33 – 35 weeks,
• All otherwise healthy
• ≤ 6 months at start of RSV season
• Outcome: Wheezing in first year of life
• Relative reduction 61% wheezing days
• Respiratory episodes same, less coinfectionsMaarten O. et al. NEJM 2013; 368:1791-1799
35
Palivizumab and Wheezing in Healthy Preterm Infants
Maarten O. et al. NEJM 2013; 368:1791-1799
Palivizumab: Wheezing 6 years Follow-up
• ≥ 3 doses of palivizumab
– 15.3% treated v. 31.6% untreated wheezing
• No prevention of atopic asthma
• Nonrandomized
• Untreated group
– More likely to have smoker in household
– More family hx of asthma
Hiroyuki Mochizuki ; Satoshi Kusuda ; Kenji Okada ; Shigemi Yoshihara ; Hiroyuki Furuya ; Eric A. F. Simões. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. American Journal of Respiratory and Critical Care Medicine, February 2017
36
Does Palivizumab Prevent Asthma?
• 429 infants, GA 32-35 weeks randomized to prophylaxis or placebo
• No major effect on asthma or lung function at 6 years
– 10.3% placebo v. 9.9% treated.
Scheltema N et al. Lancet, Respiratory April 2018. p 257-264
Pediatrics November 2014, VOLUME 134 / ISSUE 5From the American Academy of Pediatrics Clinical Practice Guideline
40
Supportive Care
• Saline nose drops, bulb suctioning
• Frequent hand washing
• Limit visitors
• No cigarette exposure
• No antibiotics, antihistamines, decongestants, nasal vasoconstrictors
Presenter’s toolbox – royalty freeWikicommons
Inpatient Treatment
41
Hospitalization Rates
• 1-2% of all USA infants hospitalized with RSV
• 20-30% of premature infants are hospitalized with RSV disease
Hall CB. RSV. Textbook of Pediatric Infectious Disease
Indications for Hospitalization
• Age less than 3 months
• Gestational age less than 34 weeks
• Cardiopulmonary disease or immunodeficiency
• Respiratory rate higher the 70 breaths/min
• Wheezing and respiratory distress with O2saturations below 92% on room air
• Hypercarbia
• Atelectasis or consolidation on CXR
42
Predictors of Severity
Increased Severity• Younger age
• Dehydration
• Work of breathing (retractions)
• Tachycardia (HR > 97% for age)
Mild Disease• Adequate oral intake
• Age ≥ 2 months
• Hx of eczema
• Initial O2 sat of at least 94%
• Lower respiratory rate
• No Hx of intubation
• No or mild retractionsWalsh P, Rothenberg SJ, O'Doherty S, Hoey H, Healy R. Eur J Emerg Med. 2004;11(5):265–272.Mansbach JM, Clark S, Christopher NC, et al. Pediatrics. 2008;121(4):680–688.
• Bronchodilator
– Albuterol
– Salbutamol
• Epinephrine
Don’t Use These
• Corticosteroids
• Chest physiotherapy
• Antibiotics
Pediatrics November 2014, VOLUME 134 / ISSUE 5From the American Academy of Pediatrics Clinical Practice Guideline
43
Clearly Effective Treatments
• Supportive care
• Hydration
• Supplemental oxygen
Turner T., et al. Aust Fam Physician 37. (6): 6-13.2008
Supportive
• Nasal suctioning to clear upper airway
• Monitor for apnea, hypoxemia, and impending respiratory failure
• Normalize body temperature
• Rehydrate with oral or intravenous fluids
• Monitor hydration status
44
IV Fluids
• Severe respiratory difficulties
• Respiratory rate greater than 80 beats per minute
• Fatigue during feeding
Fitzgerald DA et al. Med J Aust. 2004;180(8):399–404 Purchased Clip Art
Oxygen
• Supplemental oxygen is not necessary if SpO2 exceeds 90%
• Continuous pulse oximetry optional
– Headbox or tent
• Mechanical ventilation if
– PaCO2 ≥ 55 mmHg
– PaO2 ≤ 70 on 60% O2Pediatrics November 2014, VOLUME 134 / ISSUE 5
From the American Academy of Pediatrics Clinical Practice Guideline
Presenters toolbox – royalty free
45
High Flow Oxygen?
Standard Flow High-Flow
Up to 2 L/min 2 L/min/Kg for FIO2 of 92% to 98%
Escalation of care 23% Escalation of care 12%
Same LOS, stay in ICU, or duration of oxygen therapy
Franklin D et al. NEJM 2018; 378:1121-1131
How Much O2 and How Long?
• O2 saturations improve 66 hours after other problems resolve
• AAP suggest less intense oximetry as infants improve otherwise
• Home 02 being studiedPediatrics Vol. 125 No. 2 February 1, 2010 pp. 342 -349
46
Choosing Wisely Campaign for Hospitalized Infants
• No CXR’s in childhood asthma or bronchiolitis– Radiation and false positives
• No bronchodilators in bronchiolitis– Minimal or no benefit
• No systemic steroids in children under 2 – harmful and no benefit
• No continuous pulse oximetry unless on O2
– Over diagnosis hypoxemia
Nebulized 3% Hypertonic Saline
• Improve mucociliary transit time in cystic fibrosis
• Osmotic hydration
• Double blind study of 127 patients showed no difference in LOS between 3% and saline
• Don’t use in ER, may use inpatient
– Better with longer LOS
Montefiore Medical Center. "Common treatment for bronchiolitis ineffective at reducing length of hospital stay, study suggests." ScienceDaily. ScienceDaily, 6 May 2013
47
Antibiotics
• Frequently used because of fever, young age, concerns over secondary bacterial infection
• Secondary infection uncommon (0%-3.7%)
• Given to 50-80% of hospitalized infants
• Most common secondary infection is UTI
• Antibiotics should not be used in children with bronchiolitis unless there is a concomitant bacterial infection
PEDIATRICS Vol. 118 No. 4 October 2006, pp. 1774-1793Caroline Breese Hall, M.D. N Engl J Med 2007; 357:402-404
Take Home Points
• Avoid daycare, older siblings, cigarettes, formula, poverty, prematurity, and crowds to lessen risk of bronchiolitis
• Transmission is mostly direct contact
• Most treatment is supportive; supportive, hydration and oxygen
• Palivizumab is indicated for certain premature infants during RSV season
Chronic Obstructive Pulmonary Disorder (COPD): A Breath of Fresh Air
Clare Hawkins, MD, MSC, FAAFP
ACTIVITY DISCLAIMERThe material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note that medical information is constantly changing; the information contained in this activity was accurate at the time of publication. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.
The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.
2
DISCLOSUREIt is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity.
All individuals in a position to control content for this session have indicated they have no relevant financial relationships to disclose.
The content of my material/presentation in this CME activity will not include discussion of unapproved or investigational uses of products or devices.
Clare Hawkins, MD, MSC, FAAFPLead physician, Aspire Health in Texas
Dr. Hawkins splits his time between practicing family medicine in private practice in Houston, Texas, and managing a palliative care home-visiting service in Texas and Louisiana for Aspire Health. He also manages Renaissance Physicians, a large independent physician association (IPA). He is a recent past president of the Texas Academy of Family Physicians, is a member of the AAFP’s Commission on Health of the Public and Science, and is a chair of the commission’s Subcommittee on Clinical Practice Guidelines. With 30 years of experience as a family medicine educator and more than 15 years serving as faculty for the AAFP, Dr. Hawkins has presented on a variety of medical topics. In addition, he has a long-term interest in the physician-patient relationship and physician resilience.
3
Learning Objectives1. Evaluate patients who are current or former smokers, and
those who develop frequent viral infections, for symptoms that may indicate COPD or related conditions.
2. Interpret and validate results in symptomatic patients.
3. Prepare treatment plans that include a combination approach to therapy for patients who have COPD.
4. Counsel patients who have COPD on the importance of quitting smoking and receiving annual vaccinations for influenza and pneumonia.
Audience Engagement SystemStep 1 Step 2 Step 3
4
Epidemiology of COPD
• Third leading cause of death in the US1
• 15.2% of adults had a diagnosis of COPD in 20102
• $36 billion dollars annually in 2010, and costs are expected to rise to $49 billion for medical costs alone by 20203
• Worldwide, an estimated 74 million deaths were caused by COPD in 20154
1 CDC 2016, 2Adeloye et al 2015, 3Ford et al, 2015, 4WHO Fact sheet 2016
COPD Phenotypes• Overlapping
• Some COPD without classic features
NoPhenotype
Chronic Bronchitis
Asthma
Emphysema
5
2. Testing for COPD
• Physical Exam*
• Office Spirometry
• Other Pulmonary Function Testing
• Chest Xray & CT
• ECG*Hilleman 1995
Diagnosis• Spirometry as the mainstay of diagnosis• Simple, inexpensive, but sometimes
confusing• Spirometry classification of COPD patients by
GOLD COPD has utility but does not easily explain illness trajectory
• Health Status Measures assist (CAT and MRC dyspnea Scale)
6
Three Numbers• FVC: Forced Vital Capacity• FEV1: Amount breathed out in 1 second• FEV1/FVC: How much of your lung’s air can be
exhaled in the first second– Measure of caliber or function of airway – NOT A COMPARISON TO REFERENCE
• Loss of Functioning Tissue – Atelectasis– Large Neoplasm– Resection
Pleural– Effusion– Fibrosis
Chest Wall– Kyphoscoliosis– Neuromuscular
Disease– Trauma
Extrathoracic– Abdominal
Distension– Obesity
13
Coding and ReimbursementDiagnosis Code
Cough 786.2
Simple chronic bronchitis 491.0
Mucopurulent chronic bronchitis 491.2
Acute bronchitis 466.0
Chronic obstructive pulmonary disease 496.0
Shortness of breath 786.5
Restrictive lung disease 515
Asthma 493.91
Coding and ReimbursementProcedure CPT Code Reimbursement*
Single spirometry 94010 $32.82
Pre‐post spirometry 94060 $57.71
Pulmonary stress test simple 94620 $71.77
Medication administration bronchodilator supply separate 94640 $13.34
Demonstration / instruction 94664 $14.79
Smoking Cessation <8x/ yr 99406 $12.98
Equipment Cost
Office spirometer $1,500 – 2,500
Reimbursements based on Medicare payments 2009 Trailblazer Spirometry cost estimated from several vendors
14
COPD Assessment Test (CAT): • CAT: An 8-item measure of health status impairment in
COPD • CCQ: Clinical COPD Questionnaire (CCQ):
– Self-administered questionnaire developed to measure clinical control in patients with COPD (http://www.ccq.nl)
• mMRC dyspnea: Breathlessness Measurement using the Modified British Medical Research Council :
– relates well to other measures of health status and predicts future mortality risk
http://catestonline.org
CAT (COPD Assessment Test) I never cough 1 2 3 4 5 I cough all the time
I have no phlegm in my chest at all 1 2 3 4 5 My chest is full of phlegm
My chest does not feel tight at all 1 2 3 4 5 My chest feels very tight
When I walk up a hill or one flight of stairs I am not breathless
1 2 3 4 5 When I walk up a hill or one flight of stairs I am very breathless
I am not limited doing any activities at home
1 2 3 4 5 I am very limited doing activities at home
I am confident leaving my home despite my lung condition
1 2 3 4 5 I am not at all confident leaving my home because of my lung condition
I sleep soundly 1 2 3 4 5 I don’t sleep soundly because of my lung condition
I have losts of energy 1 2 3 4 5 I have no energy at all
15
CATscore
Impact level Possible management considerations
<10 Low
• Smoking Cessation• Annual influenza vaccination• Reduce exposure to exacerbation risk factors• Therapy as warranted by further clinical assessment.
10–20 Medium
• Reviewing maintenance therapy – is it optimal?• Referral for pulmonary rehabilitation• Ensuring best approaches to minimising and managing exacerbations
• Reviewing aggravating factors –still smoking?
21–30 High • Referral to specialist care (if you are in general practice) • Additional pharmacological treatments
mMRC Dyspnea Scale
0 I only get breathless with strenuous exercise
1 I get short of breath when hurrying on the level or walking up a slight hill
2 I walk slower than people of the same age on the level because of my breathlessness, or I have to stop for breath when walking on my own pace on the level
3 I stop for breath after walking about 100 meters or a few minutes on the level
4 I am too breathless to leave the house or I am breathless when dressing or undressing
16
Prognosis Model in COPD
Characteristics SpirometricClass
Exac/ yr CAT mMRC
A Low Risk, Less Symptoms Gold 1‐2 <1 <10 0‐1
B Low Risk, More Symptoms Gold 1‐2 <1 >10 >2
C High Risk, Less Symptoms Gold 3‐4 >2 <10 0‐1
D High Risk, More Symptoms Gold 3‐4 >2 >10 >2
17
3. Treatment Plans
• Medications for Stable COPD• Medications for COPD Exacerbations• Pulmonary Rehabilitation• Oxygen Therapy• Comorbidities• End of Life Care
GOALS
• Relieving symptoms• Slowing disease progression• Enhancing exercise tolerance and
functional status• Preventing and treating complications• Improving overall health
• COPD as third most common cause of death• A story without a (well defined), Beginning,
Middle or End– Dyspnea at Rest– Frequent Exacerbations– Weight Loss – Recurrent Intubation/ Ventilation
Case II Roger
• Roger is a 65 yo with advanced COPD, who you have seen for many years, and treated with multiple inhalers, oxygen and a few hospitalizations for exacerbations
• He has begun to lose weight and has severe exercise restriction in spite of maximal treatment
• Can you enter a conversation about prognosis? • How?
30
Case II Roger 65 COPD “D” • Multiple inhalers, oxygen and a
few hospitalizations for exacerbations
• Has begun to lose weight and has severe exercise restriction in spite of maximal treatment
• How would you bring up the topic?
Adobe Stock License # 64486308
AES Question #3
How would you bring up the topic?A. Tell him, there is nothing more medicine can
doB. Discuss how if he is intubated he will never
come off the ventilatorC. Say, “I’m worried about you because I see
signs that your disease is getting much worse”
31
Illness Trajectory: Chronic IllnessOrgan Failure COPD or CHF
Exacerbation
Introducing The Topic• “After looking at what has been going on in the
past year, I think we should talk about where this appears to be going”
• “How do you feel about continuing to go to the hospital?”
• “When this happens again do you want to go on a breathing machine?”
• “Since we know that COPD will likely take your life, have you thought what it will be like to die?”
32
AES Question #4
The only thing which changes the natural history of COPD is;
A. Anti-inflammatory therapy
B. Smoking cessation
C. Combined LABA and LAMA therapy
D. Pulmonary rehabilitation
Adapted from: Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645–1648.
33
4. Smoking Cessation & Vaccination
• Ask: At every visit about smoking status
• Advise: the hazards and impact of smoking
• Assess: readiness to quit, set a quit-date
• Assist: prescribe
• Arrange: follow-up in person, telephonic or on-linehttps://www.cdc.gov/tobacco/quit_smoking/cessation/nqdw/index.htm
Quitting Smoking Among Adults — United States, 2000–2015 MMRW. January 6, 2017 / 65(52);1457–1464https://www.cdc.gov/mmwr/volumes/65/wr/mm6552a1.htm?s_cid=mm6552a1_w
34
Varenicline (Chantix)
Initiate regimen 1 week before quit smoking date Days 1-3: 0.5 mg PO qDay Days 4-7: 0.5 mg PO BID Day 8 to end of treatment: 1 mg PO BID If quitting is successful after 12 weeks,
continue another 12 weeks at 1 mg q12hr
Varenicline (Chantix) SLOW QUIT METHOD: reduce smoking by 50%
from baseline within the first 4 weeks, by an additional 50% in the next 4 weeks Side Effects Psychiatric relative contraindication (depression/
suicide) Seizure contraindication Reduce dose if GFR < 30 0.5 mg/d increase to bid If on hemodialysis; maximum 0.5 mg / d
• Pradella CO, Belmonte GM, Maia MN, Delgado CS, Luise AP, Nascimento OA, et al. Home-Based Pulmonary Rehabilitation for Subjects With COPD: A Randomized Study. Respiratory Care. 2015;60(4):526-32.
38
References• Centers For Disease Control and Prevention. Chronic obstructive
pulmonary disease (COPD). 2016. Accessed at https://www.cdc.gov/copd/index.html on 15 May 2017.
• Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):020415.
• Ford E, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. CHEST. 2015;147(1):31-45.
• World Health Organization. Chronic obstructive pulmonary disease (COPD): Fact Sheet. 2016. Accessed at http://www.who.int/mediacentre/factsheets/fs315/en/ on 15 May 2017.
References• Leuppi JD. Short-term vs Conventional Glucocorticoid
Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease The REDUCE Randomized Clinical Trial. JAMA. 2013;309(21):2223-2231
• Roman M, Larraz C, Gomez A, Ripoll J, Mir I, Miranda EZ, et al. Efficacy of pulmonary rehabilitation in patients with moderate chronic obstructive pulmonary disease: a randomized controlled trial. BMC Family Practice. 2013;14:21.
39
References• Wellington Respiratory Study. Thorax
2008;63:761-7 • ACP Updates Guideline on Diagnosis and
Management of Stable COPD Aug 2, 2011 www.aafp.org/fpm 2012
• Armstrong C. ACP guideline on stable COPD. Am Fam Physician. 2012 Jan 15;85(2):204-205.
References
• Lee H, Kim J, Tagmazyan K. Treatment of stable COPD: the GOLD guidelines. Am FamPhysician. 2013;88(10):655-663.
• Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir Med. 2000;94(5):496-500.
40
References • Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors
for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2013;11:CD002309.
• Martinez FJ, Calverley PM, Goehring UM, Brose M, FabbriLM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentrerandomised controlled trial. Lancet. 2015;385(9971):857-66.
• Anthonisen NR, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987 Feb;106(2):196-204.
References• Qaseem A, WT, Weinberger SE, Hanania NA, Criner G, van der
Molen T, Marciniuk DD, Denberg, T, Schünemann H, Wedzicha W, MacDonald R, Shekelle P; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011 Aug 2;155(3):179-91. 2011.
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645–1648
1
Pneumonia: The Forgotten Killer
William R. Sonnenberg, MD, FAAFP
ACTIVITY DISCLAIMERThe material presented here is being made available by the American Academy of Family Physicians for educational purposes only. Please note that medical information is constantly changing; the information contained in this activity was accurate at the time of publication. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.
The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.
2
DISCLOSUREIt is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflict of interest (COI), and if identified, conflicts are resolved prior to confirmation of participation. Only those participants who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this CME activity.
All individuals in a position to control content for this session have indicated they have no relevant financial relationships to disclose.
The content of my material/presentation in this CME activity will not include discussion of unapproved or investigational uses of products or devices.
William R. Sonnenberg, MD, FAAFPFamily physician, Titusville, Pennsylvania; Clinical Assistant Professor of Family and Community Medicine, Penn State College of Medicine, Hershey, Pennsylvania
Dr. Sonnenberg earned his medical degree from the University of Pittsburgh and completed his family medicine residency at McKeesport Hospital in Pennsylvania. A former president of the Pennsylvania Academy of Family Physicians, he has been in private practice in the Titusville, Pennsylvania, area since 1983. In 2017, he was a featured speaker about pneumonia and inflammatory bowel disease in three issues of the AAFP’s FP Audio™. His lectures at national meetings have been selected for publication by Audio-Digest seven times. 2018 marks his 11th time presenting at the AAFP’s annual meeting.
3
Learning Objectives1. Monitor the health of patients who have weakened immune systems to mitigate risk
factors that increase their risks of developing pneumonia.
2. Prescribe appropriate empiric therapy for CAP based on suspected pathogen and local susceptibility patterns.
3. Identify risk factors for multidrug-pathogens in patients who have HAP or VAP.
4. Prescribe appropriate antibiotic therapy for HAP or VAP based on risk factors for multidrug-resistant pathogens, predominant pathogens in the clinical setting and local susceptibility patterns.
5. Provide appropriate vaccines for prevention of pneumococcal pneumonia and influenza per current guidelines.
Audience Engagement SystemStep 1 Step 2 Step 3
4
Target Audience
• Alabama
• Illinois
• Maine
• Michigan
• Washington
Jim Henson
• May 4, 1990 had sore throat
• May 13, saw doctor in North Carolina, aspirin suggested
• May 15, 2am, SOB and coughing blood
• 5 am ventilator
• Died may 16 1:21 am
5
Maimonides and Pneumonia
• Acute fever
• Sticking pain in the chest
• Short breaths
• Serrated pulse
• Cough mostly with sputum
Epidemiology
• 8th leading cause of death in USA
• Most common infection-related mortality
• Main cause of sepsis worldwide
• 2nd leading cause of hospitalization
• 2nd highest % of ER visits admitted
• Most in winter months
• 52,700 deaths in 2007
• $17 billion per year
Am Fam Physician. 2011 Jun 1;83(11):1299-1306
6
8th Leading Cause of Death - 2013
27,682
41,32553,282
0
10,000
20,000
30,000
40,000
50,000
60,000
Prostate Cancer Breast Cancer Pneumonia
DEA
THS
30 Day Readmission Rate
23.5%20.0%
15.5% 14.7%
0%
5%
10%
15%
20%
25%
CHF COPD Pneumonia AMI
Agency for Healthcare Research and Quality, Feb 23, 2016
$2 Billion Cost$2 Billion Cost
7
Stagnation
• No mortality decrease since routine use of penicillin – 14%
• Guidelines work!
• 28,661 pneumonias, 7,719 admissions
• 30 day mortality for admitted patients
• 11.0% v 14.2% (RR 0.69)Dean, NC et al. Am J Med. 2001 Apr 15;110(6):451-7
Community Acquired Pneumonia
8
Risk Factors for CAP
• Male
• Underweight
• >65 years
• Smoking
• Alcohol
• Immunosuppression
• COPD
• HIV
• Asplenia
• Contact with children
• Bad teeth
• Crowding (>10/household)Torres A, Peetermans WE, Viegi G, Blasi F. Thorax. 2013;68(11):1057-1065
Smoking and Invasive Pneumococcus
Current Smokers
Cigs/day Odds Ratio
1-14 2.3
15-24 3.7
>24 5.5
All 4.1
Passive Smokers
Hours/day Odds Ratio
≤4 2.4
>4 3.9
All 2.5
J. Pekka Nuorti, M.D, et al. N Engl J Med 2000; 342:681-689
Pneumonia in Elderly• Weaker immunity, less symptoms• Insidious onset• Chest pain uncommon• Fever may be absent, 30%• May have normal WBC• Cough weak or absent• Delirium common• Sputum minimal or absent
Daniel M. Musher, M.D., and Anna R. Thorner, M.D. NEJM 2014; 371:1619-1628
14
Osler on Pneumonia
"In old age, pneumonia may be latent, coming on without a chill; the cough and expectoration are slight.. ..”
“In senile and alcoholic patients, the temperature may be low but the brain symptoms pronounced.”
CAP Pathogens
Typical
• S. pneumoniae
• H. influenzae
Atypical
• Mycoplasma
• Chlamydophilia pneumonia
• Legionella
• Viruses
15
Atypicals
• Don’t Gram Stain
• Don’t grow on routine culture
• Present in 25% of all pneumonias
• Always treat
Typical v. Atypical PneumoniaTypical
• Memorable onset• Unilateral• Pleuritic• Cough with purulent phlegm• Fever, chills, sweats• Dyspnea• Few extrapulmonary symptoms
Keedy K, et al. Poster presented at: 19th Annual MAD-ID Conference; May 5-7, 2016; Orlando, FL.
Macrolides in Pneumonia?• High pneumococcal resistance• Decrease inflammatory mediators and adhesion molecules• Many retrospective studies show reduced morbidity and
mortality• 187 pts, crude mortality 5.6% v. 23.6% with azithromycin
• Clarithromycin probably should not be used• Interaction with CCB’s – kidney injury, hypotension, death• Statin interactions
Shorr AF, et al. BMJ Open 2013
38
Fluoroquinolones Have Issues
• Hypertoxic C. diff; NAP1
• Worse than clindamycin
• Prolonged QT interval
• Tendon rupture and tendonitis
• Black box neuropathy warning
• Aortic dissection, aneurysm
Risk Factors Resistant Pneumococcus
• Age > 65 years• β-lactam, macrolide, or
fluoroquinolone past 3-6 months• Alcoholism• Comorbidities• Immunosuppressive illness or
therapy• Exposure to child in day care
39
Steroids For Inpatient CAP• Meta analysis 13 RCT trials (>2000 pts)
• 20-60 mg prednisone or equivalent
• All-cause mortality RR 5.3% v. 7.9%
• Only benefited severe pneumonia 7.4% vs. 22.0%
• Mechanical ventilation RR 3.1% v. 5.7%
• ARDS 0.4% vs. 3.0%
• Shortened hospital stay one day.
Siemieniuk RAC et al. Ann Intern Med 2015 Oct 6
Using Steroids in CAP
• Worsens influenza and aspergilla pneumonia
• Best in severe pneumonia
• Dose
• IV Methylprednisolone 0.5 mg/kg every 12 hours
• PO prednisone 50 mg daily
• Duration 5-7 days
40
Switch to Oral Therapy• Meet following criteria for 24 hours
• Able to ingest oral medications• HR <100, SBP > 90 • RR < 25• O2 sat > 90%, pO2 > 60 on room air or low-
flow O2 via nasal cannula, or return to baseline O2 for pts on long-term O2 therapy
• Return to baseline cognition• Temp < 100.9⁰F (38.3⁰C)
Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. JAMA. 2016;315(6):593–602
Duration of Antibiotic Therapy• Minimum of 5 days
• 7 days if fever persists after 4 days
• Expect improvement at day 3
Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:Suppl 2:S27-S72
41
Response to Therapy
• Expect improvement in 3 days
• 6% - 15% may not respond
• Pneumococcal pneumonia
• Cough resolves in 8 days
• Crackles clear in 3 weeks
Risk Factors for Response Failure• Multilobar
• Cavitation
• Pleural effusion
• Liver disease
• Leukopenia
• High PSI IndexMenéndez R et al. Thorax. 2004;59(11):960
42
Treatment Failures, Further Evaluation
• Repeat history – travel, pet exposure
• Repeat CXR, sputum and blood cultures
• Chest CT
• Bronchoscopy
• Lung biopsy
Clin Infect Dis. 2007;44 Suppl 2:S27
Cardiac Complications of Pneumonia
• Influenza and bacterial pneumonia
• MI and afib in 7-10% of admitted VA patients
• Worsening heart failure in 20%
• Up regulation of cytokines
• Afib usually resolves in few weeks
Daniel M. Musher, M.D., and Anna R. Thorner, M.D. N Engl J Med 2014; 371:1619-162
43
Stable for Discharge?• Temp > 37.8⁰C• RR > 24• HR > 100• SBP ≤ 90• O2 sat < 90% on room air• Can‘t eat• No mental status improvement
• If one parameter of instability present at discharge then
• Death rate 14.6% v. 2.1%
• Readmission 14.6% v. 6.5%
Dagan E et al. Scand J Infect Dis. 2006;38(10):860